ORNBV Stock Analysis: Orion | HE
Drug Manufacturers - General | HE, Finland | Market Cap: 11.356m EUR | 12M Return: 16.4% | FI0009014377 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.3M
EPS Trend: 95.5%
Qual. Beats: 0
Rev. Trend: 98.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Orion Oyj is a Finnish pharmaceutical company headquartered in Espoo, founded in 1917, that develops, manufactures, and markets human and veterinary pharmaceuticals as well as active pharmaceutical ingredients (APIs) across Europe, North America, and other international markets. The pharmaceutical sector is characterized by significant R&D investment and long product development cycles, with companies often relying on licensing partnerships to extend the commercial reach of key assets.
The companys product portfolio spans multiple therapeutic areas, including oncology (Nubeqa for prostate cancer, Fareston for breast cancer), neurology (Parkinsons disease treatments such as Entacapion, Stalevo, Comtess, and Comtan), respiratory care (the Easyhaler inhaler portfolio for asthma and COPD), cardiology (Simdax for acute decompensated heart failure), and pain/inflammation (Burana, Trexan). It also markets self-care products such as non-prescription medicines, dietary supplements, and skincare items, reflecting a diversified consumer health segment common among established European pharma firms.
Orion operates a veterinary pharmaceuticals business offering products like Bonqat, Clevor, Domosedan, and Dexdomitor, and provides API manufacturing and contract manufacturing services to third parties. The company has entered licensing agreements with Bayer for the development and commercialization of darolutamide (Nubeqa) and with Tenax Therapeutics for oral levosimendan (TNX-103) targeting pulmonary hypertension in heart failure with preserved ejection fraction, illustrating the asset-partnering model frequently used in the pharmaceutical industry to share development risk and broaden geographic reach.
- Nubeqa royalties surge as Bayer expands prostate cancer label globally
- Easyhaler respiratory franchise drives European volume growth
- Stalevo and Comtess face accelerating generic erosion in Europe
| Net Income: 587.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA 7.49 > 1.0 |
| NWC/Revenue: 36.21% < 20% (prev 27.83%; Δ 8.37% < -1%) |
| CFO/TA 0.25 > 3% & CFO 471.6m > Net Income 587.1m |
| Net Debt (17.1m) to EBITDA (798.0m): 0.02 < 3 |
| Current Ratio: 2.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (140.9m) vs 12m ago 0.74% < -2% |
| Gross Margin: 65.93% > 18% (prev 61.84%; Δ 4.09% > 0.5%) |
| Asset Turnover: 116.9% > 50% (prev 101.9%; Δ 15.03% > 0%) |
| Interest Coverage Ratio: 195.2 > 6 (EBIT TTM 741.7m / Interest Expense TTM 3.80m) |
| A: 0.40 (Total Current Assets 1.20b - Total Current Liabilities 454.5m) / Total Assets 1.87b |
| B: 0.62 (Retained Earnings 1.17b / Total Assets 1.87b) |
| C: 0.42 (EBIT TTM 741.7m / Avg Total Assets 1.76b) |
| D: 2.10 (Book Value of Equity 1.27b / Total Liabilities 604.7m) |
| Altman-Z'' = 9.67 = AAA |
| DSRI: 1.18 (Receivables 543.8m/374.9m, Revenue 2.06b/1.68b) |
| GMI: 0.94 (GM 61.84% / 65.93%) |
| AQI: 0.89 (AQ_t 0.11 / AQ_t-1 0.13) |
| SGI: 1.23 (Revenue 2.06b / 1.68b) |
| TATA: 0.06 (NI 587.1m - CFO 471.6m) / TA 1.87b) |
| Beneish M = -2.83 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at EUR 79.60 with a total of 194,544 shares traded. Over the past week, the price has changed by -1.49%, over one month by +0.51%, over three months by +12.83% and over the past year by +16.41%.
Current recommended Stop Loss: 77.30 (which is 2.9% or 1.3 ATR below the current price).
Orion has no consensus analysts rating.
P/E Trailing = 19.3541
P/E Forward = 29.4985
P/S = 5.5183
P/B = 9.1471
P/EG = 5.7296
Revenue TTM = 2.06b EUR
EBIT TTM = 741.7m EUR
EBITDA TTM = 798.0m EUR
Long Term Debt = 105.9m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 29.3m EUR (from shortTermDebt, last quarter)
Debt = 147.3m EUR (from shortLongTermDebtTotal, last quarter) + Leases 14.6m
Net Debt = 17.1m EUR (calculated: Debt 147.3m - CCE 130.2m)
Enterprise Value = 11.4b EUR (11.4b + Debt 147.3m - CCE 130.2m)
Interest Coverage Ratio = 195.2 (Ebit TTM 741.7m / Interest Expense TTM 3.80m)
EV/FCF = 29.27x (Enterprise Value 11.4b / FCF TTM 388.6m)
FCF Yield = 3.42% (FCF TTM 388.6m / Enterprise Value 11.4b)
FCF Margin = 18.89% (FCF TTM 388.6m / Revenue TTM 2.06b)
Net Margin = 28.54% (Net Income TTM 587.1m / Revenue TTM 2.06b)
Gross Margin = 65.93% ((Revenue TTM 2.06b - Cost of Revenue TTM 701.0m) / Revenue TTM)
Gross Margin QoQ = 65.16% (prev 60.81%)
Tobins Q-Ratio = 6.07 (Enterprise Value 11.4b / Total Assets 1.87b)
Interest Expense / Debt = 2.58% (Interest Expense 3.80m / Debt 147.3m)
Taxrate = 20.31% (149.6m / 736.6m)
NOPAT = 591.1m (EBIT 741.7m * (1 - 20.31%))
Current Ratio = 2.64 (Total Current Assets 1.20b / Total Current Liabilities 454.5m)
Debt / Equity = 0.12 (Debt 147.3m / totalStockholderEquity, last quarter 1.27b)
Debt / EBITDA = 0.02 (Net Debt 17.1m / EBITDA 798.0m)
Debt / FCF = 0.04 (Net Debt 17.1m / FCF TTM 388.6m)
Total Stockholder Equity = 1.17b (last 4 quarters mean from totalStockholderEquity)
RoA = 33.36% (Net Income 587.1m / Total Assets 1.87b)
RoE = 50.02% (Net Income TTM 587.1m / Total Stockholder Equity 1.17b)
RoCE = 57.96% (EBIT 741.7m / Capital Employed (Equity 1.17b + L.T.Debt 105.9m))
RoIC = 43.93% (NOPAT 591.1m / Invested Capital 1.35b)
WACC = 6.53% (E(11.4b)/V(11.5b) * Re(6.59%) + D(147.3m)/V(11.5b) * Rd(2.58%) * (1-Tc(0.20)))
Discount Rate = 6.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 10.77 | Cagr: 0.14%
[DCF] Terminal Value 77.97% ; FCFF base≈320.4m ; Y1≈367.2m ; Y5≈540.5m
[DCF] Fair Price = 74.47 (EV 8.13b - Net Debt 17.1m = Equity 8.12b / Shares 109.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.54 | EPS CAGR: 50.14% | SUE: 0.15 | # QB: 0
Revenue Correlation: 98.55 | Revenue CAGR: 24.36% | SUE: 0.35 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.08 | Chg30d=+1.47% | Revisions=+25% | Analysts=4
EPS current Year (2026-12-31): EPS=4.02 | Chg30d=+0.20% | Revisions=+25% | GrowthEPS=+12.9% | GrowthRev=+11.0%
EPS next Year (2027-12-31): EPS=4.75 | Chg30d=+1.15% | Revisions=+25% | GrowthEPS=+18.1% | GrowthRev=+13.2%
[Analyst] Revisions Ratio: +50% (up=3, down=0)